Rico Laage

TL;DR: Patients with ischaemic stroke 4·5-9 h from stroke onset or wake-up stroke with salvageable brain tissue who were treated with alteplase achieved better functional outcomes than did patients given placebo, and this increase in the rate of symptomatic intracerebral haemorrhage did not negate the overall net benefit of thrombolysis.

TL;DR: A biological assay termed split TEV, engineered inactive fragments of the NIa protease from the tobacco etch virus that regain activity only when coexpressed as fusion constructs with interacting proteins, is developed and monitored.

TL;DR: A novel function of GM-CSF is uncovered, which acts as a neuroprotective protein in the central nervous system (CNS), and is remarkably reminiscent of the recently discovered functionality of two other hematopoietic factors, erythropoietin and granulocyte colony-stimulating factor in the CNS.

TL;DR: G-CSF showed the expected peripheral pharmacokinetic and pharmacodynamic profiles, with a strong increase in leukocytes and monocytes, and in parallel, the cytokine profile showed a significant decrease of interleukin-1.

TL;DR: In a large cohort of >1800 patients with ischemic stroke, initial lesion size is a strong and independent predictor of stroke outcome in a statistical regression model that also accounts for age and National Institutes of Health Stroke Scale at baseline.